FDG-PET predicts response to chemo in Hodgkin's disease
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.
Dr. Andrea Gallamini and colleagues in Italy and Denmark enrolled 260 advanced Hodgkin's lymphoma patients scheduled to receive six cycles of chemotherapy. Patients underwent F-18 FDG-PET imaging before the first and after the second chemo cycle. Those with positive and negative FDG-PET results at the second chemo cycle recorded a two-year progression-free survival rate of 12.8% and 95%, respectively (J Clin Oncol 2007;25[24]:3746-3752).
The study shows that FDG-PET can be a useful prognostic tool that will help sort patients into appropriate management paths, researchers said.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
